利德曼拟收购祥瑞生物不超70%股权

Core Viewpoint - Beijing Lide Man Bio-Pharmaceutical Co., Ltd. plans to acquire up to 70% of shares from certain shareholders of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, aiming to gain control over the target company [1] Group 1: Transaction Details - The funding for the acquisition will be sourced from the company's own funds and supplemented by bank merger loans [1] - Prior to the transaction, the company did not hold any shares in the target company; post-transaction, the target company will become a subsidiary [1] - The transaction is still in the planning stage, with key elements such as transaction scheme and price yet to be negotiated [1] Group 2: Target Company Overview - Xiansheng Xiangrui is primarily engaged in in vitro diagnostic reagents and human vaccines, with key products including tuberculin purified protein derivative and BCG purified protein derivative [1] - The products are mainly used in tuberculosis screening, diagnosis, treatment, and innovative vaccine fields [1] Group 3: Strategic Implications - Upon completion of the transaction, the company's IVD business segment will include tuberculosis diagnostic screening, expanding integrated tuberculosis treatment and innovative vaccine business [1] - This acquisition is expected to enhance the company's overall competitiveness and align with the interests of the company and its shareholders [1]